Int J Hematol. 2022 Jan;115(1):43-53. doi: 10.1007/s12185-021-03224-5. Epub 2021 Sep 21.

All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.

International journal of hematology

Vilma Dembitz, Hrvoje Lalic, Barbara Tomic, Tomislav Smoljo, Josip Batinic, Klara Dubravcic, Drago Batinic, Antonio Bedalov, Dora Visnjic

PMID: 34546543 DOI: 10.1007/s12185-021-03224-5

Abstract

All-trans retinoic acid (ATRA)-based therapy for acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), is the most successful example of differentiation therapy. Although ATRA can induce differentiation in some non-APL AML cell lines and primary blasts, clinical results of adding ATRA to standard therapy in non-APL AML patients have been inconsistent, probably due to use of different regimens and lack of diagnostic tools for identifying which patients may be sensitive to ATRA. In this study, we exposed primary blasts obtained from non-APL AML patients to ATRA to test for differentiation potential in vitro. We observed increased expression of differentiation markers, indicating a response to ATRA, in four out of fifteen primary AML samples. Three samples in which CD11b increased in response to ATRA had an inversion of chromosome 16 as well as the CBFB-MYH11 fusion gene, and the fourth sample was from a patient with KMT2A-rearranged, therapy-related AML. In conclusion, we identified a subgroup of non-APL AML patients with inv(16) and CBFB-MYH11 as the most sensitive to ATRA-mediated differentiation in vitro, and our results can help identify patients who may benefit from ATRA treatment.

© 2021. Japanese Society of Hematology.

Keywords: ATRA1; Acute myeloid leukemia2; CBFB-MYH11 5; Differentiation3; Inversion of chromosome 164

References

1. Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, Daver N. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10:506–25. https://doi.org/10.1158/2159-8290.CD-19-1011 . - PubMed
2. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci. 1980;77:2936–40. https://doi.org/10.1073/pnas.77.5.2936 . - PubMed
3. Nguyen CH, Grandits AM, Purton LE, Sill H, Wieser R. All-trans retinoic acid in non-promyelocytic acute myeloid leukemia: driver lesion dependent effects on leukemic stem cells. Cell Cycle. 2020;19:2573–88. https://doi.org/10.1080/15384101.2020.1810402 . - PubMed
4. di Martino O, Welch JS. Retinoic acid receptors in acute myeloid leukemia therapy. Cancers. 2019. https://doi.org/10.3390/cancers11121915 . - PubMed
5. Pan P, Chen X. Nuclear receptors as potential therapeutic targets for myeloid leukemia. Cells. 2020. https://doi.org/10.3390/cells9091921 . - PubMed
6. Milligan DW, Wheatley K, Littlewood T, Craig JIO, Burnett AK. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood. 2006;107:4614–22. https://doi.org/10.1182/blood-2005-10-4202 . - PubMed
7. Burnett AK, Hills RK, Green C, Jenkinson S, Koo K, Patel Y, Guy C, Gilkes A, Milligan DW, Goldstone AH, et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and C. Blood. 2010;115:948–56. https://doi.org/10.1182/blood-2009-08-236588 . - PubMed
8. Schlenk RF, Dohner K, Kneba M, Gotze K, Hartmann F, del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, et al. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica. 2009;94:54–60. https://doi.org/10.3324/haematol.13378 . - PubMed
9. Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst H-A, et al. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07–04 study. Ann Hematol. 2016;95:1931–42. https://doi.org/10.1007/s00277-016-2810-z . - PubMed
10. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196 . - PubMed
11. Bolis M, Terao M, Pattini L, Garattini E, Fratelli M. The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients. Blood Cancer J. 2019;9:76. https://doi.org/10.1038/s41408-019-0241-5 . - PubMed
12. Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, Lewis TA, Schajnovitz A, Jain E, Lee D, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167:171-186.e15. https://doi.org/10.1016/j.cell.2016.08.057 . - PubMed
13. U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=AML&term=DHODH&cntry=&state=&city=&dist= . Accessed 8 Jan 2020 - PubMed
14. Lalic H, Dembitz V, Lukinovic-Skudar V, Banfic H, Visnjic D. 5-Aminoimidazole-4-carboxamide ribonucleoside induces differentiation of acute myeloid leukemia cells. Leuk Lymphoma. 2014;55:2375–83. https://doi.org/10.3109/10428194.2013.876633 . - PubMed
15. Dembitz V, Tomic B, Kodvanj I, Simon JA, Bedalov A, Visnjic D. The ribonucleoside AICAr induces differentiation of myeloid leukemia by activating the ATR/Chk1 via pyrimidine depletion. J Biol Chem. 2019;294:15257–70. https://doi.org/10.1074/jbc.RA119.009396 . - PubMed
16. Dembitz V, Lalic H, Kodvanj I, Tomic B, Batinic J, Dubravcic K, Batinic D, Bedalov A, Visnjic D. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts. BMC Cancer. 2020;20:1090. https://doi.org/10.1186/s12885-020-07533-6 . - PubMed
17. Boutzen H, Saland E, Larrue C, de Toni F, Gales L, Castelli FA, Cathebas M, Zaghdoudi S, Stuani L, Kaoma T, et al. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. J Exp Med. 2016;213:483–97. https://doi.org/10.1084/jem.20150736 . - PubMed
18. Ma HS, Greenblatt SM, Shirley CM, Duffield AS, Bruner JK, Li L, Nguyen B, Jung E, Aplan PD, Ghiaur G, et al. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood. 2016;127:2867–78. https://doi.org/10.1182/blood-2015-05-646786 . - PubMed
19. Zhou J, Yiying Quah J, Ng Y, Chooi J-Y, Hui-Min Toh S, Lin B, Zea Tan T, Hosoi H, Osato M, Seet Q, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2020;105:2286–97. https://doi.org/10.3324/haematol.2019.230482 . - PubMed
20. Qian S-X, Li J, Hong M, Qiu H-R, Fan L, Xu W. Acute myeloid leukemia in four patients with t(8;21) treated with all-trans retinoic acid as a single agent. Leuk Lymphoma. 2008;49:998–1001. https://doi.org/10.1080/10428190801959018 . - PubMed
21. El Hajj H, Dassouki Z, Berthier C, Raffoux E, Ades L, Legrand O, Hleihel R, Sahin U, Tawil N, Salameh A, et al. Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. Blood. 2015;125:3447–54. https://doi.org/10.1182/blood-2014-11-612416 . - PubMed
22. Martelli MP, Gionfriddo I, Mezzasoma F, Milano F, Pierangeli S, Mulas F, Pacini R, Tabarrini A, Pettirossi V, Rossi R, et al. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells. Blood. 2015;125:3455–65. https://doi.org/10.1182/blood-2014-11-611459 . - PubMed
23. Opatz S, Bamopoulos SA, Metzeler KH, Herold T, Ksienzyk B, Bräundl K, Tschuri S, Vosberg S, Konstandin NP, Wang C, et al. The clinical mutatome of core binding factor leukemia. Leukemia. 2020;34:1553–62. https://doi.org/10.1038/s41375-019-0697-0 . - PubMed
24. di Martino O, Niu H, Hadwiger G, Kuusanmaki H, Ferris MA, Vu A, Beales J, Wagner C, Menéndez-Gutiérrez MP, Ricote M, et al. Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica. 2021;106:1008–21. https://doi.org/10.3324/haematol.2020.264432 . - PubMed
25. Nguyen CH, Grandits AM, Vassiliou GS, Staber PB, Heller G, Wieser R. Evi1 counteracts anti-leukemic and stem cell inhibitory effects of all-trans retinoic acid on Flt3-ITD/Npm1c-driven acute myeloid leukemia cells. Biomed. 2020. https://doi.org/10.3390/biomedicines8100385 . - PubMed
26. Verhagen HJMP, Smit MA, Rutten A, Denkers F, Poddighe PJ, Merle PA, Ossenkoppele GJ, Smit L. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. Blood. 2016;127:458–63. https://doi.org/10.1182/blood-2015-07-653840 . - PubMed
27. Sakamoto K, Imamura T, Yano M, Yoshida H, Fujiki A, Hirashima Y, Hosoi H. Sensitivity of MLL-rearranged AML cells to all-trans retinoic acid is associated with the level of H3K4me2 in the RARα promoter region. Blood Cancer J. 2014;4:e205–e205. https://doi.org/10.1038/bcj.2014.25 . - PubMed
28. Fujiki A, Imamura T, Sakamoto K, Kawashima S, Yoshida H, Hirashima Y, Miyachi M, Yagyu S, Nakatani T, Sugita K, et al. All-trans retinoic acid combined with 5-Aza-2′-deoxycitidine induces C/EBPα expression and growth inhibition in MLL-AF9-positive leukemic cells. Biochem Biophys Res Commun. 2012;428:216–23. https://doi.org/10.1016/j.bbrc.2012.09.131 . - PubMed
29. Morosetti R, Park DJ, Chumakov AM, Grillier I, Shiohara M, Gombart AF, Nakamaki T, Weinberg K, Koeffler HP. A novel, myeloid transcription factor, C/EBPε, is upregulated during granulocytic, but not monocytic, differentiation. Blood. 1997;90:2591–600. https://doi.org/10.1182/blood.V90.7.2591 . - PubMed
30. Rethmeier A, Aggerholm A, Olesen LH, Juhl-Christensen C, Nyvold CG, Guldberg P, Hokland P. Promoter hypermethylation of the retinoic acid receptor β2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFβ–MYH11 fusion transcripts. Br J Haematol. 2006;133:276–83. https://doi.org/10.1111/j.1365-2141.2006.06014.x . - PubMed
31. Cao Y, Liu Y, Shang L, Wei W, Shen Y, Gu Q, Xie X, Dong W, Lin Y, Yue Y, et al. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis. Biomed Pharmacother. 2020;125: 109878. https://doi.org/10.1016/j.biopha.2020.109878 . - PubMed
32. Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, et al. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial. J Clin Oncol. 2019;38:257–70. https://doi.org/10.1200/JCO.19.01053 . - PubMed

Publication Types

• Journal Article

Grant support

• IP-2016-06-4581/Hrvatska Zaklada za Znanost
• DOK-2018-01-9599/Hrvatska Zaklada za Znanost
• DOK-2020-01-2873/Hrvatska Zaklada za Znanost
• GA KK01.1.1.01.0007/Hrvatska Zaklada za Znanost